AIM ImmunoTech Inc. (AIMI)
OTCMKTS
· Delayed Price · Currency is USD
0.0400
+0.0100 (33.33%)
Apr 17, 2025, 4:00 PM EDT
AIM ImmunoTech Revenue
In the year 2024, AIM ImmunoTech had annual revenue of $170.00K, down -15.84%. AIM ImmunoTech had revenue of $45.00K in the quarter ending December 31, 2024, a decrease of -30.77%.
Revenue
170.00K
Revenue Growth
-15.84%
P/S Ratio
11.95
Revenue / Employee
7.73K
Employees
23
Market Cap
2.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 170.00K | -32.00K | -15.84% |
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
Glass House Brands | 200.90M |
BioStem Technologies | 210.49M |
American Oncology Network | 1.76B |
AIM ImmunoTech News
- 12 days ago - AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - GlobeNewsWire
- 15 days ago - AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewsWire
- 15 days ago - NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire
- 18 days ago - AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewsWire
- 7 weeks ago - AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - GlobeNewsWire
- 7 weeks ago - AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - GlobeNewsWire